logo
    • English
      • 简体中文
      • 繁體中文
  • Home
  • Articles
    • Insights
    • Client Press Releases
    • Client Coverage
  • Interviews
    • CEO Interview
    • PDAC Interview
  • Clients
    • Featured Companies
    • In-depth Analysis
  • Markets
    • Stock Tracker
    • Markets at a glance
    • Investing 101
      • Investing in Mining 101
        • Gold and Precious Metals
        • Electric and Battery Metals
        • Base Metals
        • Other Mining Subsectors
  • METALS 100
  • GCFF Event
    • Next Event
    • Past Events
  • Home
  • Biotechnology
Filter

Biotechnology

Categories

Sectors

Locations

Exchange

Sandisk Stock Halved, Yet Analysts Overwhelmingly Say ‘Buy’

Insider Cashes Out, Hedge Fund Piles In: The Two Faces of Olema After a 300% Rally

Mar 16, 2026

Life Science

10 China stocks to ride the capital-returns upcycle

Mar 16, 2026

Life Science

This Popular ETF Quietly Boosted Its Healthcare Stake – High-Yield Dividend Stocks Are the New Favorite

Logos Bought, Alpine Sold: Is Immunovant a Buy or a Red Flag?

Mar 15, 2026

Life Science

数字医疗行业能否回暖?Hinge Health上市表现引关注

Three Berkshire-Related Stocks Worth Watching: Chevron, Domino’s Pizza, and DaVita

Mar 14, 2026

Consumer Goods, Life Science

Oil shock pops chemicals: CF, DOW, LYB, WLK, OLN

Mar 13, 2026

Consumer Goods, Life Science

Stocks Ignore War While Bonds Price the Ambush

Mar 13, 2026

Consumer Goods, Life Science

Netflix NFLX drops $600M on Ben Affleck AI. Why now?

Mar 13, 2026

Consumer Goods, Life Science

AI驱动未来医疗,BioNTech股价应声上涨近4%

Novo Nordisk Partners with Hims & Hers: Can Turning a Foe into a Friend Reverse the Downturn?

Mar 13, 2026

Life Science

Novo Nordisk: At 11x P/E, a Golden Entry or a Value Trap?

Is GeneDx, the Stock Cathie Wood Bought for 7 Straight Days, Actually Cheap?

Mar 12, 2026

Life Science

Breaking Down VKTX: 188% Upside, Pipeline Progress and Key Risks

The Obesity Drug War Goes Oral: Why Eli Lilly’s Orforglipron Could Steal the Spotlight from Novo

Mar 11, 2026

Life Science

Weight-Loss Truce: Hims & Hers Wins Novo Nordisk Deal, Soars 40%

Weight-Loss Truce: Hims & Hers Wins Novo Nordisk Deal, Soars 40%

Mar 9, 2026

Life Science

This Cathie Wood-Favored Gene-Editing Stock Is Up 47% This Year. Is It Poised to Take Off?

This Cathie Wood-Favored Gene-Editing Stock Is Up 47% This Year. Is It Poised to Take Off?

Mar 8, 2026

Life Science

高股息医疗股怎么选?强生与美敦力的优势与挑战

Alleviating Doctors’ Paperwork, Amazon Accelerates AI Healthcare Initiatives

Mar 5, 2026

Life Science

Up 100% Then Down 24%: Is the Moderna Pullback a Buying Opportunity?

Amtagvi’s Complex Path: Why Iovance Is Either a Home Run or a Strikeout

Mar 5, 2026

Life Science

Shorted-to-the-hilt KalVista rockets 39% as Chiesi swoops in with $1.9bn cash bid

Post-Casgevy Era: CRISPR’s Quandary vs. Vertex’s Moat

Mar 4, 2026

Life Science

Buffett’s UnitedHealth Bet Pays Off as Insurer Crushes Q1 Estimates

Despite Gains, These 2 Stocks Are Still Worth Buying

Mar 4, 2026

Consumer Goods, Life Science

WIX, MSFT, GOOGL, AMZN, TSLA: AI tape lights up

Mar 4, 2026

Consumer Goods, Life Science

Alphabet vs. Meta: Which Digital Ad Titan Is the Smarter Buy Right Now?

Why Novartis Outshines Amarin as a Safe Bet in a Volatile Market

Mar 3, 2026

Life Science

  • ‹‹ Previous
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next ››

We connect Investors to Opportunities.

Financial Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

 
QuoteMedia logo

Head Office

  • 2209 – 1111 Alberni Street
    Vancouver, BC Canada V6E 4V2
  • Phone: (604) 488-8878
  • Fax: (604) 488-0868
  • Toll Free: 1 (866) 833-5517
  • Email: [email protected]

Shanghai Office

  • 06 - 607, 6/f. No.800 Shangcheng
    Road Pudong New District Shanghai,
    China
  • Phone: 021-68883919
  • Fax: 021-68882879
  • Email: [email protected]

Important Links

  • Privacy Policy
  • Terms of Use
  • Content Partner
  • NAI500 Investor Relations Services
  • About Us
  • Contact Us

© 2026 NAI Interactive Ltd. All Rights Reserved

gcff

logo

Website Design Vancouver by Nirvana Canada